Alicia Grande - 22 Mar 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
VP, Treasurer and CFO
Signature
/s/ Alicia Grande
Issuer symbol
CPRX
Transactions as of
22 Mar 2023
Net transactions value
-$656,518
Form type
4
Filing time
24 Mar 2023, 17:00:14 UTC
Previous filing
17 Feb 2023
Next filing
30 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $2,575 +3,260 +6.4% $0.7900* 53,817 22 Mar 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $53,497 -3,260 -6.1% $16.41 50,557 22 Mar 2023 Direct F1, F3
transaction CPRX Common stock, par value $0.001 per share Options Exercise $30,434 +38,524 +76% $0.7900* 89,081 22 Mar 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $636,031 -38,524 -43% $16.51 50,557 22 Mar 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -3,260 -0.23% $0.000000 1,442,574 22 Mar 2023 Common Stock 3,260 $0.7900 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -38,524 -2.7% $0.000000 1,404,050 22 Mar 2023 Common Stock 38,524 $0.7900 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold in various lots from $16.40 to $16.425 per share. The listed sale price represents a weighted average price for the shares sold.
F2 Shares were sold in various lots from $16.50 to $16.555 per share. The listed sale price represents a weighted average price for the shares sold.
F3 Shares were sold to cover exercise price of options, tax withholding requirements and for personal reasons. Shares were not sold as a result of any disagreement with the Company and Ms. Grande remains an officer of the Company.
F4 Options vested in two annual tranches beginning on June 15, 2017.